언어 선택

HLA-A*0201 & B2M & EW (QLQNPSYDK)

HLA-A*0201 & B2M & EW (QLQNPSYDK) 제품 목록

속성
Protein (1)
제품 라이브러리
온라인 (1)
종
Human (1)
태그
His Tag & Avi Tag (1)
마커
Biotin-labeled (1)

제품 번호	종	발현 시스템	제품 설명	단백질 구조	순도	특성
HLE-H82E4	Human	HEK293	Biotinylated Human HLA-A*02:01&B2M&EW (QLQNPSYDK) Complex Protein (Monomer, MALS verified)

총 수량1

HLA-A*0201 & B2M & EW (QLQNPSYDK)분자 배경

The EW peptide (QLQNPSYDK) is a Pin1-specific inhibitor derived from the CD99 protein. It functions by blocking Pin1's enzymatic activity, making it a valuable research tool for investigating Pin1-related pathways in cancer and neurodegeneration, and a prototype for therapeutic development.

임상 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	적응증	임상 시험
SHR-A1921	SHR-A1921; SHRA1921; SHR-1921	Phase 3 Clinical		Solid tumours; Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Salivary Gland Neoplasms; Neoplasms; Breast Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Metastatic breast cancer; Brain metastases; Carcinoma, Non-Small-Cell Lung	상세
ESG-401	ESG-401; STI-3258	Phase 3 Clinical	Shanghai Escugen Biotechnology Co Ltd	Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Metastatic breast cancer	상세
OBI-992	OBI-992	Phase 2 Clinical	Obi Pharma Usa Inc	Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung	상세
HS-20105	HS-20105; HS20105	Phase 2 Clinical	Hansoh BioMedical R&D Company	Solid tumours	상세
IBI130	IBI130; IBI-130	Phase 2 Clinical	Innovent Biologics(Suzhou) Co Ltd	Solid tumours; Neoplasm Metastasis	상세
Anti TROP2 antibody drug conjugate ADC（Fudan University）		Phase 2 Clinical	Fudan University	Triple Negative Breast Neoplasms	상세
9MW-2921	9MW2921; 9MW-2921	Phase 2 Clinical	Mabwell (Shanghai) Bioscience Co Ltd	Solid tumours	상세
MHB036C	MHB-036C	Phase 2 Clinical	Minghui Pharmaceutical Pty Ltd	Solid tumours; Lung Neoplasms	상세
BAT-8008	BAT-8008; BAT8008	Phase 2 Clinical	Bio-Thera Solutions Ltd	Solid tumours; Triple Negative Breast Neoplasms	상세
DB-1305	DB1305; BNT325; DB-1305; BNT-325	Phase 2 Clinical		Solid tumours	상세
BIO-106	BIO-106	Phase 2 Clinical	Hangzhou Baikai Biopharmaceutical Co Ltd	Solid tumours; Neoplasms	상세
BL-M02D1		Phase 2 Clinical	Baili-Bio (Chengdu) Pharmaceutical Co Ltd	Solid tumours; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Breast Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung	상세
LCB-84	LCB-84	Phase 2 Clinical	Legochem Biosciences Inc	Solid tumours	상세
FDA018 Antibody Drug Conjugate	FDA018-ADC; FDA-018-ADC	Phase 2 Clinical	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd	Solid tumours; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Neoplasm Metastasis	상세
DAC-002	DAC-002; JS-108	Phase 1 Clinical	Hangzhou Dac Biotech Company Ltd	Solid tumours; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma	상세
JSKN-016	JSKN016; JSKN-016	Phase 1 Clinical	Jiangsu Alphamab Biopharmaceuticals Co Ltd	Solid tumours; Neoplasms	상세
DXC-1002	DXC1002; DXC-1002	Phase 1 Clinical	Hangzhou Dac Biotech Company Ltd	Solid tumours	상세
FZ-AD004	FZ-AD004	Phase 1 Clinical	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd	Solid tumours	상세
MT-302	MT-302	Phase 1 Clinical	Myeloid Therapeutics Inc	Carcinoma; Colonic Neoplasms; Breast Neoplasms; Lung Neoplasms	상세

시판 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	가장 빠른 브랜드 이름	가장 빠른 승인 국가	가장 빠른 적응증	가장 빠른 승인 회사	가장 빠른 승인 날짜	적응증	임상 시험
Sacituzumab govitecan	IMMU-132; TROP-2-SN-38; IMMU0132; GS-0132; IMMU-0132	Approved		Trodelvy, 拓达维, TRODELVY	United States	Triple Negative Breast Neoplasms	Immunomedics Inc	2020-04-22	Mesothelioma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Thymoma; Brain metastases; Esophageal Squamous Cell Carcinoma; Endometrial Neoplasms; Metastatic breast cancer; Bile Duct Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Klatskin Tumor; Urinary Bladder Neoplasms; Liver Failure; Thyroid Carcinoma, Anaplastic; Salivary Gland Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Glioblastoma; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Biliary Tract Neoplasms; Ovarian Neoplasms; Solid tumours	상세
Sacituzumab tirumotecan	SKB-264; MK-2870; SKB264; sac-TMT	Approved	Klus Pharma Inc	佳泰莱	Mainland China	Triple Negative Breast Neoplasms	Sichuan Kelun-Biotech Biopharmaceutical Co Ltd	2024-11-22	Triple Negative Breast Neoplasms; Gastrointestinal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Colorectal Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; Biliary Tract Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Carcinoma; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Solid tumours	상세